ESMO: Novartis’ Pluvicto slows hormone-sensitive prostate cancer progression
18th October 2025 Uncategorised 0Novartis has shared detailed data showing its radioligand therapy Pluvicto could slow the progression of certain hormone-sensitive prostate cancers ahead of a planned application with the FDA. More: ESMO: Novartis’ Pluvicto slows hormone-sensitive prostate cancer progression Source: fierce
read more